Cargando…

Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease

Metabolic-associated fatty liver disease (MAFLD) is a complex condition characterized by steatosis and metabolic disturbances. Risk factors such as diabetes, cigarette smoking, and dyslipidaemia contribute to its development and progression. Effective and safe therapies for MAFLD are urgently needed...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodrigues Albuquerque, Edilson, Ratti da Silva, Gustavo, de Abreu Braga, Fernanda, Pelegrini Silva, Ester, Sposito Negrini, Karina, Rodrigues Fracasso, Julia Amanda, Pires Guarnier, Lucas, Jacomassi, Ezilda, Ribeiro-Paes, João Tadeu, da Silva Gomes, Roberto, Gasparotto Junior, Arquimedes, Lívero, Francislaine Aparecida dos Reis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653969/
https://www.ncbi.nlm.nih.gov/pubmed/38026733
http://dx.doi.org/10.1155/2023/8840427
_version_ 1785136529382834176
author Rodrigues Albuquerque, Edilson
Ratti da Silva, Gustavo
de Abreu Braga, Fernanda
Pelegrini Silva, Ester
Sposito Negrini, Karina
Rodrigues Fracasso, Julia Amanda
Pires Guarnier, Lucas
Jacomassi, Ezilda
Ribeiro-Paes, João Tadeu
da Silva Gomes, Roberto
Gasparotto Junior, Arquimedes
Lívero, Francislaine Aparecida dos Reis
author_facet Rodrigues Albuquerque, Edilson
Ratti da Silva, Gustavo
de Abreu Braga, Fernanda
Pelegrini Silva, Ester
Sposito Negrini, Karina
Rodrigues Fracasso, Julia Amanda
Pires Guarnier, Lucas
Jacomassi, Ezilda
Ribeiro-Paes, João Tadeu
da Silva Gomes, Roberto
Gasparotto Junior, Arquimedes
Lívero, Francislaine Aparecida dos Reis
author_sort Rodrigues Albuquerque, Edilson
collection PubMed
description Metabolic-associated fatty liver disease (MAFLD) is a complex condition characterized by steatosis and metabolic disturbances. Risk factors such as diabetes, cigarette smoking, and dyslipidaemia contribute to its development and progression. Effective and safe therapies for MAFLD are urgently needed. Pereskia grandifolia has shown potential as an alternative treatment, but its effectiveness against liver disease remains unexplored. This research aims to determine the hepatoprotective properties of P. grandifolia using a model of MAFLD. The study was carried out through various phases to assess the safety and efficacy of the ethanol-soluble fraction of P. grandifolia. Initially, an in vitro assay was performed to assess cell viability. This was followed by an acute toxicity test conducted in rats to determine the safety profile of the extract. Subsequently, the anti-inflammatory properties of P. grandifolia were examined in macrophages. For the MAFLD study, diabetic Wistar rats were made diabetic and exposed to a high fat diet and cigarette smoke, for 4 weeks. During the last 2 weeks, the rats were orally given either the vehicle (negative control group; C-), P. grandifolia (30, 100, and 300 mg/kg), or insulin in addition to simvastatin. A basal group of rats not exposed to these risk factors was also assessed. Blood samples were collected to measure cholesterol, triglycerides, glucose, ALT, and AST levels. Liver was assessed for lipid and oxidative markers, and liver histopathology was examined. P. grandifolia showed no signs of toxicity. It demonstrated anti-inflammatory effects by inhibiting phagocytosis and macrophage spreading. The MAFLD model induced liver abnormalities, including increased AST, ALT, disrupted lipid profile, oxidative stress, and significant hepatic damage. However, P. grandifolia effectively reversed these changes, highlighting its potential as a therapeutic agent. These findings emphasize the significance of P. grandifolia in mitigating hepatic consequences associated with various risk factors.
format Online
Article
Text
id pubmed-10653969
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-106539692023-11-09 Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease Rodrigues Albuquerque, Edilson Ratti da Silva, Gustavo de Abreu Braga, Fernanda Pelegrini Silva, Ester Sposito Negrini, Karina Rodrigues Fracasso, Julia Amanda Pires Guarnier, Lucas Jacomassi, Ezilda Ribeiro-Paes, João Tadeu da Silva Gomes, Roberto Gasparotto Junior, Arquimedes Lívero, Francislaine Aparecida dos Reis Evid Based Complement Alternat Med Research Article Metabolic-associated fatty liver disease (MAFLD) is a complex condition characterized by steatosis and metabolic disturbances. Risk factors such as diabetes, cigarette smoking, and dyslipidaemia contribute to its development and progression. Effective and safe therapies for MAFLD are urgently needed. Pereskia grandifolia has shown potential as an alternative treatment, but its effectiveness against liver disease remains unexplored. This research aims to determine the hepatoprotective properties of P. grandifolia using a model of MAFLD. The study was carried out through various phases to assess the safety and efficacy of the ethanol-soluble fraction of P. grandifolia. Initially, an in vitro assay was performed to assess cell viability. This was followed by an acute toxicity test conducted in rats to determine the safety profile of the extract. Subsequently, the anti-inflammatory properties of P. grandifolia were examined in macrophages. For the MAFLD study, diabetic Wistar rats were made diabetic and exposed to a high fat diet and cigarette smoke, for 4 weeks. During the last 2 weeks, the rats were orally given either the vehicle (negative control group; C-), P. grandifolia (30, 100, and 300 mg/kg), or insulin in addition to simvastatin. A basal group of rats not exposed to these risk factors was also assessed. Blood samples were collected to measure cholesterol, triglycerides, glucose, ALT, and AST levels. Liver was assessed for lipid and oxidative markers, and liver histopathology was examined. P. grandifolia showed no signs of toxicity. It demonstrated anti-inflammatory effects by inhibiting phagocytosis and macrophage spreading. The MAFLD model induced liver abnormalities, including increased AST, ALT, disrupted lipid profile, oxidative stress, and significant hepatic damage. However, P. grandifolia effectively reversed these changes, highlighting its potential as a therapeutic agent. These findings emphasize the significance of P. grandifolia in mitigating hepatic consequences associated with various risk factors. Hindawi 2023-11-09 /pmc/articles/PMC10653969/ /pubmed/38026733 http://dx.doi.org/10.1155/2023/8840427 Text en Copyright © 2023 Edilson Rodrigues Albuquerque et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Rodrigues Albuquerque, Edilson
Ratti da Silva, Gustavo
de Abreu Braga, Fernanda
Pelegrini Silva, Ester
Sposito Negrini, Karina
Rodrigues Fracasso, Julia Amanda
Pires Guarnier, Lucas
Jacomassi, Ezilda
Ribeiro-Paes, João Tadeu
da Silva Gomes, Roberto
Gasparotto Junior, Arquimedes
Lívero, Francislaine Aparecida dos Reis
Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease
title Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease
title_full Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease
title_fullStr Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease
title_full_unstemmed Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease
title_short Bridging the Gap: Exploring the Preclinical Potential of Pereskia grandifolia in Metabolic-Associated Fatty Liver Disease
title_sort bridging the gap: exploring the preclinical potential of pereskia grandifolia in metabolic-associated fatty liver disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653969/
https://www.ncbi.nlm.nih.gov/pubmed/38026733
http://dx.doi.org/10.1155/2023/8840427
work_keys_str_mv AT rodriguesalbuquerqueedilson bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT rattidasilvagustavo bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT deabreubragafernanda bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT pelegrinisilvaester bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT spositonegrinikarina bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT rodriguesfracassojuliaamanda bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT piresguarnierlucas bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT jacomassiezilda bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT ribeiropaesjoaotadeu bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT dasilvagomesroberto bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT gasparottojuniorarquimedes bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease
AT liverofrancislaineaparecidadosreis bridgingthegapexploringthepreclinicalpotentialofpereskiagrandifoliainmetabolicassociatedfattyliverdisease